Boston, Medtronic Differ On Views For MRI Coverage In Pacemaker Patients
This article was originally published in The Gray Sheet
Boston Scientific says it agrees with CMS' decision to refrain from covering magnetic resonance imaging in cardiac pacemaker and implantable defibrillator patients for now
You may also be interested in...
Use of magnetic resonance imaging to assess heart valve disease in Medicare patients may be an easier proposition for physicians if a June 30 CMS coverage 1proposal is adopted
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.